Al Bostami Rouba D, Abuwatfa Waad H, Husseini Ghaleb A
Department of Chemical Engineering, College of Engineering, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates.
Materials Science and Engineering Program, College of Arts and Sciences, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates.
Nanomaterials (Basel). 2022 Aug 4;12(15):2672. doi: 10.3390/nano12152672.
Cancer therapies have advanced tremendously throughout the last decade, yet multiple factors still hinder the success of the different cancer therapeutics. The traditional therapeutic approach has been proven insufficient and lacking in the suppression of tumor growth. The simultaneous delivery of multiple small-molecule chemotherapeutic drugs and genes improves the effectiveness of each treatment, thus optimizing efficacy and improving synergistic effects. Nanomedicines integrating inorganic, lipid, and polymeric-based nanoparticles have been designed to regulate the spatiotemporal release of the encapsulated drugs. Multidrug-loaded nanocarriers are a potential strategy to fight cancer and the incorporation of co-delivery systems as a feasible treatment method has projected synergistic benefits and limited undesirable effects. Moreover, the development of co-delivery systems for maximum therapeutic impact necessitates better knowledge of the appropriate therapeutic agent ratio as well as the inherent heterogeneity of the cancer cells. Co-delivery systems can simplify clinical processes and increase patient quality of life, even though such systems are more difficult to prepare than single drug delivery systems. This review highlights the progress attained in the development and design of nano carrier-based co-delivery systems and discusses the limitations, challenges, and future perspectives in the design and fabrication of co-delivery systems.
在过去十年中，癌症治疗取得了巨大进展，但仍有多种因素阻碍着不同癌症治疗方法的成功。传统治疗方法已被证明不足以抑制肿瘤生长。同时递送多种小分子化疗药物和基因可提高每种治疗方法的有效性，从而优化疗效并增强协同效应。设计了整合无机、脂质和聚合物基纳米颗粒的纳米药物，以调节包封药物的时空释放。负载多种药物的纳米载体是对抗癌症的一种潜在策略，并且将共递送系统作为一种可行的治疗方法纳入其中已显示出协同益处和有限的不良影响。此外，为实现最大治疗效果而开发共递送系统需要更好地了解合适的治疗剂比例以及癌细胞固有的异质性。尽管共递送系统比单一药物递送系统更难制备，但它可以简化临床过程并提高患者生活质量。本综述重点介绍了基于纳米载体的共递送系统在开发和设计方面取得的进展，并讨论了共递送系统设计和制造中的局限性、挑战及未来展望。
